Causal Effect Estimation and Optimal Dose Suggestions in Mobile Health by Zhu, Liangyu et al.
ar
X
iv
:2
00
7.
09
81
2v
2 
 [s
tat
.M
E]
  2
3 J
ul 
20
20
Causal Effect Estimation and Optimal Dose Suggestions
in Mobile Health
Liangyu Zhu1∗, Wenbin Lu1, Rui Song1
1Department of Statistics, North Carolina State University
Abstract
In this article, we propose novel structural nested models to estimate causal effects
of continuous treatments based on mobile health data. To find the treatment regime
that optimizes the expected short-term outcomes for patients, we define a weighted lag-
K advantage as the value function. The optimal treatment regime is then defined to be
the one that maximizes the value function. Our method imposes minimal assumptions
on the data generating process. Statistical inference is provided for the estimated
parameters. Simulation studies and an application to the Ohio type 1 diabetes dataset
show that our method could provide meaningful insights for dose suggestions with
mobile health data.
Keywords— Causal Effect; Dose Recommendation; Infinite Horizon; Mobile Health; Sequential
Decision Making
1 Introduction
There is a rapid-increasing interest in healthcare interventions using mobile apps. Mobile tech-
nologies allow physical conditions of patients to be collected in real time, measured by sensors or
self-reported by patients. Studies have shown that mobile health interventions could be beneficial
for the healthcare delivery process by improving disease management, enhancing communication
with the healthcare provider and providing more precise and individualized medication (Free et al.,
2013). However, analyzing mobile health data can be challenging because they typically have a
large number of time points, time-varying treatments, and non-definite time horizon (Luckett et al.,
2019).
One focus in analyzing mobile health data is to evaluate causal effects of mobile health interven-
tions. Generalized estimating equations (GEE) are commonly used for studying dependence of an
outcome variable on a set of covariates observed over time (Liang & Zeger, 1986; Zhao & Prentice,
1990; Liang et al., 1992; Schafer, 2006). GEE enhance the efficiency of the generalized linear
models by including into the estimation equations the correlations among repeated observations
of a subject over time. Such approaches typically require a full working correlation model and
will be computationally expensive as the time points get larger. Application of GEE in mobile
∗Email: lzhu12@ncsu.edu
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health data has been limited to time-invariant treatments (Evans et al., 2012; Carra` et al., 2016).
Liao et al. (2015) proposed the micro-randomized trial design for estimating the causal effect of
just-in-time treatments under the mobile health setting (Klasnja et al., 2015; Liao et al., 2016;
Dempsey et al., 2015). Liao et al. (2016) and Boruvka et al. (2018) defined the proximal and lagged
treatment effects for time-varying treatments with data from micro-randomized trials. A centered
and weighted estimation method based on inverse probability of treatment-estimators (Robins et al.,
2000; Murphy et al., 2001) is then proposed for estimating these causal effects.
Providing personalized treatment suggestions based on mobile health data is also of great in-
terest. Dynamic treatment regimes (DTR) have been proposed for providing sequential treatment
suggestions based on longitudinal data from randomized trials or observational data (Murphy, 2003;
Moodie et al., 2007; Kosorok & Moodie, 2015; Chakraborty & Moodie, 2013). A dynamic treat-
ment regime is a set of decision rules that decide treatments to be assigned to patients according
to their time-varying measurements during the ongoing treatment process. An optimal DTR is
the one that yields the most favorable expected mean outcome over a fixed period of time. Op-
timal dynamic treatment regimes are typically estimated by backward induction based on para-
metric models for the expected outcome (Q-learning) (Watkins & Dayan, 1992; Sutton et al., 1998;
Murphy, 2005; Schulte et al., 2014). Robustness of these methods can be further enhanced by using
semi-parametric models (Murphy, 2003; Robins, 2004; Moodie et al., 2007; Tang & Kosorok, 2012;
Schulte et al., 2014) or non-parametric models (Zhao et al., 2009). Zhao et al. (2015) avoid the
risk of model misspecification by directly maximizing a nonparametric estimation of the cumulative
reward among a predefined class of treatment regimes.
However, mobile health data usually have infinite time horizons. Sequential decision mak-
ing process in infinite horizon can be modeled as a Markov decision process (Puterman, 2014).
Ertefaie & Strawderman (2018) defined the optimal DTR in the infinite horizon as the one which
maximizes the expected cumulative discounted reward (the beneficial outcome). The optimal DTR
is estimated first by positing a parametric model for the maximum expected cumulative discounted
reward. Least square estimation equations are then constructed based on the Bellman equation
(Sutton et al., 1998). The optimization is achieved through greedy gradient Q-learning (Maei et al.,
2010). Luckett et al. (2019) proposed the V-learning method for finding the optimal DTR. They
first posit a model for the expected cumulative discounted reward of a specific treatment regime.
Then they search for the treatment regime which maximizes the estimated cumulative discounted re-
ward function within a prespecified class of treatment regimes. However, both of these two methods
are limited to discrete treatments.
There is increasing attention in how mobile interventions can help managing diseases by mon-
itoring physical conditions against high-risk events and providing frequent treatment adjustments
(Maahs et al., 2012; Levine et al., 2001). Our research is motivated by the use of mobile health
applications for diseases like diabetes and hypertension, where the main focus is to monitor adverse
events in the near future (Haller et al., 2004; Heron & Smyth, 2010). For example, for diabetes
patients, the main interest of using rapid-reacting insulin is to maintain a safe blood glucose level
within 2 hours after a meal. Existing methodologies in reinforcement learning mainly aims at max-
imizing a discounted cumulative reward, which might not be the optimal criteria for treatment
suggestions in this scenario. Furthermore, the treatments in this case are continuous and thus have
infinite number of possible values. Studies on estimating causal effects and providing treatment
suggestions under this setting are still absent.
In this article, we aim to find the treatment regime which optimizes the outcomes (or minimizes
the risk of adverse events) within a time period of near future. We first extend Boruvka et al.
(2018)’s definition of lagged treatment effect to continuous treatments and propose novel structural
nested models for estimating causal effects of continuous treatments based on mobile health data.
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We then define a weighted advantage function. The optimal treatment regime at a specific time
point is defined to be the one which optimizes the weighted advantage function. The rest of the
article is structured as follows. In section 2, we formalize the problem in a statistical framework
and present the proposed methodology for finding the optimal DTR. In section 3, we discuss the
theoretical results of the proposed estimators. Simulations are conducted and the corresponding
results are presented in section 4. In section 5, we apply the proposed method to the Ohio type 1
diabetes dataset. Discussions and conclusions are given in section 6.
2 Method
2.1 Notation
We assume that for each individual, the measurements are taken at time points with fixed time
intervals, t = 1, ..., T . Let At ∈ A denotes the treatment at decision time t, where A is a continuous
interval of possible values of doses. Xt ∈ Rp are covariates measured at time t. Yt ∈ R denotes
the outcome measured at time t following the decision At−1, t > 1. Without loss of generality, we
assume that higher values of Yt denote better outcomes. We assume that Xt and Yt are observed
simultaneously and At is a decision made after observing Xt and Yt. Thus, the observed data
for one subject are {(X1, A1),(Y2,X2, A2), . . . , (YT ,XT , AT ), (YT+1,XT+1)}. In this article, we
use capitalized letters to denote random variables and lowercase letters to denote realized values.
Let the overbar denotes the history of a random variable. For example, X¯t = (X1, ...,Xt). All
information accrued up to time t can be represented by Ht = (X¯t, Y¯t, A¯t−1). In the considered type-
1 diabetes study, At is the rapid-reacting insulin dose taken at time t. Yt measures the stability of
the blood glucose between time t − 1 and t, and Xt includes the food intake, exercise and blood
glucose levels.
To define the treatment effects, we adopt the potential outcome framework by Rubin (1974).
Xt(a¯t−1) and Yt(a¯t−1) are the potential measurements of covariates and potential outcomes at time t
had the sequence of treatments a¯t−1 been allocated to the patient, a¯t−1 ∈ At−1. At(a¯t−1) is defined
as the potential treatment at t had the sequence of a¯t−1 be allocated. This notation implicitly
assumes that the potential outcomes are not influenced by future treatments and the outcome of
one subject is not affected by the treatments received by other subjects. The latter is also known as
the stable unit treatment value assumption (SUTVA; see Rubin (1974)). For simplicity, we denote
A2(A1) by A2, At(A¯t−1) by At. Then Ht(A¯t−1) = {X1, A1, Y2(A1), X2(A1), A2(A1), . . . , Yt(A¯t−1),
Xt(A¯t−1)}.
A dynamic treatment regime pi = (pi1, ..., piT ) is a set of rules that outputs a distribution of
treatment options at each time point based on past history pit = {ppi,t(a|ht), a ∈ A}; ppi,t here
denotes the conditional density of choosing treatment a given history ht at time t. Let Ht be the
space of all possible histories. A treatment regime is deterministic if ppi,t(a|ht) = δ(a = gt(ht)), for
some gt : Ht → A, where δ(·) is the Dirac delta function. Then for simplicity of notation, we write
pit as pit = gt(ht).
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2.2 Lag k Treatment Effect
Define the conditional lag k (k ≥ 1) treatment effect of treatment a with respect to a reference
treatment a0 at time t as:
τt,k
(
a, a0,Ht(A¯t−1)
)
=
E
{
Yt+k(A¯t−1, a,Aat=at+1 , . . . , A
at=a
t+k−1)− Yt+k(A¯t−1, a0, Aat=a0t+1 , . . . , Aat=a0t+k−1)|Ht(A¯t−1)
}
. (1)
Aat=at+1 denotes the potential treatment At+1(A¯t−1, At = a), A
at=a
t+l denotes At+l(A¯t−1, At = a, A
at=a
t+1 ,
..., Aat=at+l−1), for l = 2, . . . , k−1. The expectation in Equation (1) is taken over all the possible future
treatments from time t to t + k − 1. Notice that the treatment effect defined in (1) measures the
effect of a one-time change in the decision strategy. The causal effect measuring a single-time
decision change has been extensively used in various models for intensively collected longitudinal
data (Schafer, 2006; Schwartz & Stone, 2007; Bolger & Laurenceau, 2013). Boruvka et al. (2018)
also used a similar definition for estimating the effect of mobile application notifications.
To use the observed data to estimate the lag k treatment effect, we make the following assump-
tions (Robins, 2004):
1. Consistency: The potential outcomes had the treatments given to the patient equal to the
observed treatment history are equal to the observed data. More specifically, for a¯t−1 = A¯t−1,
Yt(a¯t−1) = Yt, Xt(a¯t−1) = Xt and At(a¯t−1) = At for 2 ≤ t ≤ T , where the left sides of the
equations are the potential outcomes and right sides are the observed variables ; At time T + 1,
Y¯T+1(a¯T ) = Y¯T+1, and X¯T+1(a¯T ) = X¯T+1 for a¯t−1 = A¯t−1.
2. Positivity: All treatments a ∈ A can possibly be observed given ht for any ht ∈ Ht. More
specifically, for a ∈ A and ht ∈ Ht, ppi,t(a|ht) > 0, where ppi,t(a|ht) denotes the conditional density
for the treatment At given the historyHt = ht. In randomized trials, this assumption can be ensured
by design. In observational studies, the set of possible treatments may differ by treatment history.
The expected outcomes of a treatment regime pi cannot be estimated from the observed data when it
has a non-zero probability of suggesting treatments where ppi,t(a|ht) > 0 and p(At = a|Ht = ht) = 0.
Such treatment regimes are regarded as infeasible treatment regimes (Robins, 2004). We could then
limit our attention to feasible treatment regimes by adding constraints to the suggested treatments.
In practice, this assumption is hard to examine when A is unknown. In such scenarios, causal
inference for treatments that are uncommon in the dataset should be made with caution.
3. Sequential ignorability: The potentials outcomes {Yt+1(a¯t),Xt+1(a¯t), At+1(a¯t), ..., YT+1(a¯T )} are
independent of At conditional on Ht, for t ≤ T . This assumption is naturally satisfied in a sequen-
tially randomized study, where treatments are randomized for each time point. In an observational
study, this assumption cannot be verified and is often assumed.
Under these three assumptions, we can estimate the conditional lag k treatment effect with the
observed data for any a ∈ A (see appendix for the proof):
E
{
Yt+k(A¯t−1, a,Aat=at+1 , . . . , A
at=a
t+k−1)− Yt+k(A¯t−1, a0, Aat=a0t+1 , . . . , Aat=a0t+k−1)|Ht(A¯t−1)
}
= E(Yt+k|At = a,Ht)− E(Yt+k|At = a0,Ht). (2)
2.3 Lag K Weighted Advantage
Furthermore, we define the lag K weighted advantage to be:
τ˜t,K(a, a0, St(A¯t−1)) =
K∑
k=1
wkτt,k(a, a0,Ht(A¯t−1)),
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where K is the largest lag of interest and w1, . . . wK are predefined non-negative weights and
w1+· · ·+wK = 1. For example, if we have hourly data of diabetes patients and we want to minimize
the amount of time the blood sugar being outside 80-140 mg/dL within four hours after the dose in-
jection, we could define Yt as the percentage of time the blood sugar being outside the optimal range
at the t-th hour. Take K = 4 and w1 = w2 = w3 = w4 = 0.25. An optimal dose suggestion at time t
would be the one which maximizes the lag K weighted advantage at time t. Therefore, we define the
optimal treatment regime at time t to be: pioptt = argmaxpit τ˜t,K
{
a = pit(Ht(A¯t−1)), a0,Ht(A¯t−1)
}
.
Notice that the choice of a0 does not affect the optimal treatment regime. In this article, we take
a0 = 0 . For simplicity of notation, we write τt,k(a, 0,Ht(A¯t−1)) as τt,k(a,Ht(A¯t−1)) in the rest of
this article.
2.4 Estimation Method
We first use a nonparametric version of the structural nested models to estimate the lag k treatment
effect. The following model assumes that the lag k treatment effects for k = 1, . . . ,K depend on Ht
only through St, where St ∈ S are some summary statistics of the past history.
τt,k(a,Ht) = τk(a, St;αk, βk) = αka
2 + {βTk fk(St)}a. (3)
where fk is a qk dimensional function of St. Notice that we assume St for t = 1, . . . , T to be
from the same vector space S and the parameters in this model do not vary with t. Boruvka et al.
(2018) showed that the models for the lagged effects for different k do not constrain one another.
The motivation for using a quadratic model is that both underdosing and overdosing might lead to
unfavorable outcomes in practice. Let α = (α1, . . . , αK)
T , β = (β1, . . . , βK)
T , and w = (w1, ..., wK)
T .
Without loss of generality, we assume that f1(St) = · · · = fK(St). (Otherwise, just let f(St) be
a vector of functions which includes all the functions from {f1(St), . . . , fK(St)} and substitute
f1(St), . . . , fK(St) with f(St).) Then the weighted lag K advantage is:
τ˜K(a, St;α, β) =
K∑
k=1
wkτk(a, St, αk, βk)
= {wTα}a2 + {wTβ}T f(St)a = α˜Ka2 + β˜TKf(St)a,
where α˜K = w
Tα, β˜K = w
Tβ. Thus the lag K weighted advantage also follows a quadratic form.
Notice that under the model above, τ˜t,K
(
a, a0,Ht(A¯t−1)
)
= τ˜K(a, St;α, β) also depends on Ht only
through St. Thus the optimal treatment regime pi
opt
t = argmaxpit τ˜K(a = pit, St;α, β) also depends
onHt only through St. When α˜K < 0, the optimal dose at time t would be a deterministic treatment
regime: pioptt = −{β˜TKf(St)}/2α˜K . The parameter −β˜K,j/α˜K can be interpreted as the difference of
the optimal dosage for patients with one unit difference in the j-th term of f(St) while having all
the other covariates the same, j = 1, . . . , q where q is the dimension of f(St). When α˜K ≥ 0, the
optimal treatment falls on the edge of A.
We first present the standard structural nested models for estimating the lag k causal effect.
Let Ut+k = Yt+k − τk(At,Ht). Under the proposed model,
Ut+k(αk, βk) = Yt+k − τk(At, St;αk, βk)
= Yt+k − αkA2t − βTk fk(St)At.
According to Theorem 3.3 in Robins (2004), under the assumption of sequential randomization and
consistency, we can obtain:
E
[{
d(At,Ht)− E(d(At,Ht)|Ht)
}× {Ut+k − E(Ut+k|Ht)}] = 0, (4)
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where d(·, ·) is an arbitrary function and t ∈ {1, . . . , T + 1− k}. Assume that the data consist of n
independent subjects {H1T+1, . . . ,HnT+1} . Then we can estimate αk, βk with:
0 =Pn
T−k+1∑
t=1
{
dt+k(At,Ht)− E
(
dt+k(At,Ht)|Ht
)}× {Ut+k(αk, βk)− E(Ut+k(αk, βk)|Ht)}, (5)
where
dt+k(At,Ht) = −∂Ut+k(αk, βk)
∂(αk, βk)
=
(
A2t
Atfk(St)
)
. (6)
and Pn denotes empirical mean of a function, Png(At, St, Yt) =
∑n
i=1 g(A
i
t, S
i
t , Y
i
t )/n for any function
g(·). Since dt+k(·) depends on Ht only through St, we write it as dt+k(At, St). To apply the estima-
tion equation, we need to obtain E{dt+k(At, St)|Ht} and E(Yt+k|Ht). The traditional approach is
to use regression models to estimate these conditional expectations. However, the complexity of the
model increases as t increases, leading to a high risk of model misspecification. If nonparametric
estimators are used, the high dimension of Ht can also induce large variance. Therefore, we revise
the estimation equation by first showing the following result (See the appendix for the proof).
Theorem 1. Under model assumption (3), if the following assumption is satisfied:
At ⊥ Yt+k(a¯t+k−1)|St for a¯t+k−1 ∈ At+k−1, (7)
then for an arbitrary function d(·) : A× S → Rqk+1:
E
[{
d(At, St)− E(d(At, St)|St)
}× {Ut+k − E(Ut+k|St)}] = 0. (8)
Therefore we can estimate αk, βk with:
0 =Pn
T−k+1∑
t=1
{
dt+k(At, St)− E
(
dt+k(At, St)|St
)}× {Ut+k(αk, βk)− E(Ut+k(αk, βk)|St)},
where dt+k(At, St) is also taken to be (6). The advantage of this estimation equation is that the
dimension of St does not increase with t. Therefore we can use nonparametric estimators for
E(Ut+k|St) and E(d(At, St)|St) without imposing model assumptions on At|St and Yt+k|St. The
above equation can thus be written as:
0 =
n∑
i=1
T−k+1∑
t=1
(
Ait
2 − E(Ait2|Sit)
{Ait − E(Ait|Sit)}gk(Sit)
){
Y it+k − E(Y it+k|Sit)−
(
Ait
2 −E(Ait2|Sit)
{Ait − E(Ait|Sit)}fk(Sit)
)T (
αk
βk
)}
.
Let Bt(s) = E(A
2
t |St = s), Ct(s) = E(At|St = s), Dt,k(s) = E(Yt+k|St = s). We estimate
Bt(s), Ct(s), Dt,k(s) with kernel estimators: Bˆt(s) =
∑n
i=1A
i
t
2
KΛ(h − Sit)/{
∑n
i=1KΛ(s − Sit)},
Cˆt(s) =
∑n
i=1A
i
tKΛ(s−Sit)/{
∑n
i=1KΛ(s−Sit)}, Dˆt,k(s) =
∑n
i=1 Y
i
t+kKΛ(s−Sit)/{
∑n
i=1KΛ(s−Sit)},
where K(·) is a multivariate kernel function and KΛ(u) = |Λ|−1/2K(Λ−1/2u), Λ is a symmetric and
positive definite bandwidth matrix. We can then derive the estimated parameters:
(
αˆk
βˆk
)
=
[ n∑
i=1
T−k+1∑
t=1
(
Ait
2 − Bˆt(Sit)
{Ait − Cˆt(Sit)}fk(Sit)
)⊗2 ]−1[ n∑
i=1
T−k+1∑
t=1
(
Ait
2 − Bˆt(Sit)
{Ait − Cˆt(Sit)}fk(Sit)
){
Y it+k − Dˆt,k(Sit)
}]
.
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The estimated α˜K and β˜K can thus be calculated by ˆ˜αK =
∑K
k=1wkαˆk,
ˆ˜βK =
∑K
k=1wkβˆk.
When ˆ˜αK < 0, pi
opt
t can be estimated by pˆi
opt
t = −{ ˆ˜βTKf(St)}/2ˆ˜αK . When ˆ˜α ≥ 0, pˆioptt would be
either 0 or the maximum possible dosage. We can also estimate the parameters for the lag K
weighted advantage directly by letting U˜t+K(α˜K , β˜K) =
∑K
i=1wkYt+k − α˜KA2t − {β˜TKf(St)}At and
estimate α˜K , β˜K with:
0 =
n∑
i=1
T−K+1∑
t=1
{
dit+K(At, St)− E
(
dit+K(At, St)|Sit
)}× {U˜ it+K(β˜K)− E(U˜ it+K(β˜K)|St)},
where E
(
U˜ it+K(β˜K)|St) can be estimated similarly with kernel estimation. It is trivial to
prove that estimated α˜K and β˜K are the same with these two approaches.
Since in model (3), the parameters αk and βk are invariant across time, the estimation
equation can thus be summed over the time index t. Also notice that the kernel estima-
tion in our method averages over the n observations but not over the time index t. If
we include enough information in St, then it might be possible to assume that the condi-
tional distributions Yt+k|St and At|St are invariant across time. Then we can let:Bˆt(s) =
{∑ni=1∑Tt=1Ait2KΛ(s− Sit)}/{∑ni=1∑Tt=1KΛ(s− Sit)}, where the sum is taken over t as well
(similar for Cˆt(s) and Dˆt,k(s)). This would be more preferable when we only observe the data
of a small number of patients and each patient has a large number of observations over time.
The validity of our estimation equation is mainly based on assumptions (3) and (7). In
other words, we assume that the summary statistics of the past history St contains all the
information which influences the lag k treatment effect and the dependence between At and
Yt+k(A¯t−1, a, A
at=a
t+1 , . . . , A
at=a
t+k−1) for k = 1, . . . , K . In our simulation study, we will also
examine the performance of the model when assumption (7) is not valid.
3 Theoretical Results
In this section, we derive the consistency and asymptotic normality of the estimated pa-
rameters. For simplicity of notation, let B = {B1(S1), . . . , BT (ST )}, C = {C1(S1), . . . ,
CT (ST )}, D = {D1(S1), . . . , DT−k+1(ST )}, and Bˆ = {Bˆ1(S1), . . . , BˆT (ST )}, Cˆ = {Cˆ1(S1),
. . . , CˆT (ST )}, Dˆ = {Dˆ1(S1), . . . , DˆT−k+1(ST )} and H = HT+1. Then the solution to the
estimating equation can be written as:
(αˆk, βˆ
T
k )
T =
[
PnL1(H ; Bˆ, Cˆ)
]−1[
PnL2(H ; Bˆ, Cˆ, Dˆ)
]
,
where,
L1(H ;B,C) =
T−k+1∑
t=1
(
At
2 −Bt(St)
{At − Ct(St)}fk(St)
)⊗2
,
L2(H ;B,C,D) =
T−k+1∑
t=1
(
At
2 −Bt(St)
{At − Ct(St)}fk(St)
){
Yt+k −Dt(St)
}
.
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Let φˆk = (αˆk, βˆ
T
k )
T , and φ∗k = (α
∗
k, β
∗T
k )
T , where:(
α∗k
β∗k
)
=
{
E
[
L1(H ;B,C)
]}−1
E
[
L2(H ;B,C,D)
]
.
From Equation (8), it is trivial to obtain that (α∗k, β
∗T
k )
T are the true parameters of the model
if the model assumption (3) is correct. To derive the asymptotic normality of the estimators,
we need the following regularity assumptions:
Assumption 1. The marginal density of St, pSt, is uniformly bounded away from 0 for all
t: infs∈S pSt(s) > 0.
Assumption 2. As Λ→ 0, the kernel function satisfies the following equations:
infs{
∫
Vs K(v)dv} = 1 − O(Λ
1
2 ); sups{
∫
Vs vK(v)dv} = O(1); sups{
∫
Vs K
2(v)dv} = O(1);
sups{
∫
Vs vK
2(v)dv} = O(1), where Vs = {v : s− Λ 12 v ∈ S} for s ∈ S and v is a vector with
the same number of dimensions as s.
Assumption 3. E(At|St = s), E(A2t |St = s), E(A4t |St = s), E(Yt+k|St = s), E(Y 2t+k|St = s),
pSt(s) as functions of s are uniformly bounded for s ∈ S. The first derivatives of these
functions are also uniformly bounded.
Assumption 1 is to ensure that the kernel estimators Bˆt(s), Cˆt(s), Dˆt(s) do not diverge
to infinity because of pˆSt(s) =
1
n
∑n
i=1KΛ(s − Sit), which converges in probability to pSt(s),
on the denominator. The first equation in Assumption 2 ensures the unbiasedness of the
kernel estimator. When S = Rd, this assumption is satisfied by most commonly used kernel
functions. However, when S is bounded, a kernel function defined on Rd might fail to satisfy
this assumption. The rest three equations ensure that the limit distributions of the kernel
estimators exist. Assumption 3 ensures that the higher order terms of the Taylor expansion
of the kernel estimators converge to zero. Then we have the following theorem.
Theorem 2. If assumptions 1–3 are satisfied, and Λ satisfies n|Λ| → ∞ and Λ → 0 as
n→∞, then √n(φˆk − φ∗k) converges to a normal distribution with mean 0 and variance:
E−1
{
H ;L1(B,C)
}
Σ(H ;φ∗k, B, C,D)E
−1
{
L1(H ;B,C)
}
,
where,
Σ(H ;φ∗k, B, C,D) = Var
{
PnL1(H ;B,C)φ
∗
k − PnL2(H ;B,C,D)
}
.
The variance covariance function above can be estimated consistently with:
P
−1
n
{
L1(H ; Bˆ, Cˆ)
}
Σ(H ;φ∗k, Bˆ, Cˆ, Dˆ)P
−1
n
{
L1(H ; Bˆ, Cˆ)]
}
.
The proof of the theorem is in the appendix.
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4 Simulation Studies
We evaluate the proposed method using a simulation study. The following generative model
simulates an observational study where the treatment at each time point is correlated with
past treatments and covariates. For each individual, data (X1, A1, ..., XT+1, YT+1) are gener-
ated as follows: X1 ∼ Normal(0, σ2), A1 ∼ Uniform(0, 1); For t ≥ 1, Xt+1 ∼ Normal(η1Xt +
η2At, σ
2), At+1 ∼ Normal(τ1Xt+1+τ2At, σ2); Yt+1 = θ1Xt +θ2At−1−At(At −β0− β1Xt)+ǫt+1,
where ǫt ∼ Normal(0, σ2) and the correlation between ǫt1 and ǫt2 for any t1, t2 ∈ {2, . . . , T+1}
is σ|t1−t2|/2. Here we assume that the data is observed starting from t = 1 and the dosages
have been transformed so that At ∈ A = R.
Notice that when St = Xt and θ2 = 0, assumption (7) is satisfied (Proof is provided in
the appendix). Under the simulation setting above, the true value for the lag 1 treatment
effect is: τt,1(a, St) = −a2 + (β0 + β1St)a. We can also prove that for k ≥ 2, the lag k effect
under this generative model also follows a quadratic form (See appendix for details). We
take σ = 0.5, θ1 = 0.8, θ2 = 0, η1 = −0.2, η2 = 0.2, τ1 = 1, τ2 = −0.5, β0 = 0, β1 = 2
and St = Xt. The true parameters for the lag 1, lag 2, lag 3 treatment effects can thus be
calculated: (α1, β1,0, β1,1) = (−1, 0, 2); (α2, β2,0, β2,1) = (−0.21, 0.16,−0.08); (α3, β3,0, β3,1) =
(−0.0125,−0.08,−0.03). The true parameters for the lag 3 weighted advantage with w1 =
w2 = w3 = 1/3 are (α˜3, β˜3,0, β˜3,1) = (−0.4075, 0.0267, 0.63).
We generate the dataset with T = 50 and sample size n = 100, 200, 400. We take St = Xt
and use the proposed method to estimate the treatment effects for lag 1, 2 and 3. We use the
Gaussian kernel KΛ(s) = (2π)
−q/2|Λ|−1/2 exp(−sTΛs/2), where q = 1 is the dimension of St,
and f(St) = St. In practice, different kernels can be used, which usually will lead to similar
results. Here we chose the Gaussian kernel over the others mainly for its computational
simplicity. Λ is a q × q diagonal matrix with Λj,j = λ2j . We take λj = 0.305 × n−1/3sd(St,j),
j = 1, . . . , q. The simulation is replicated for 200 times with each sample size 1. The results
are presented in Table 1.
As presented in Table 1, the proposed method was able to estimate the parameters with
small bias. The standard deviation of the estimated parameters decreased with the sample
size increasing. The standard errors estimated with our covariance function provided a
close estimate of the standard deviation. The 95% confidence intervals provided a coverage
of the true parameters close to 95% in most scenarios. However, the estimated standard
errors slightly underestimated the standard deviation, leading to an under-coverage for the
confidence intervals. From the proof of Theorem 2 in the appendix, we see that the variance
of the estimated parameters consist of two parts, the variance from the estimation equation
and the variance from the kernel estimation. The latter part of the variance converges to 0
as n goes to infinity and is thus excluded from the asymptotic variance formula. However,
when the sample size is not large enough, excluding this part of the variance might lead to
underestimation of the variance, as supported by the simulation result.
Table 2 presents the estimated parameters for the lag 3 weighted advantage with w1 =
w2 = w3 = 1/3 from 200 replicates for each sample size. For each replicate, we obtain
πˆoptt = − ˆ˜βTKSt/(2 ˆ˜αK) and calculate the lag 3 weighted advantage of this suggested treatment
regime. The lag 3 weighted advantage is calculated on a test dataset with 5000 subjects
1The R code for the simulation can be found in https://github.com/lz2379/Mhealth.
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Table 1: Simulation results from 200 replicates for observational studies.
αk βk,0 βk,1
k n Bias1 SD1 SE1 CP Bias1 SD1 SE1 CP Bias1 SD1 SE1 CP
1 100 0.9 16.5 14.8 93.0 0.9 9.3 9.3 95.0 1.1 39.6 35.0 95.0
200 -0.4 11.1 10.4 93.5 0.3 6.8 6.3 91.0 -0.3 25.7 24.0 92.0
400 0.4 7.9 7.4 91.5 -0.1 4.5 4.3 92.0 -0.1 18.3 16.7 93.5
2 100 1.7 31.6 29.0 92.5 -1.0 23.0 22.3 93.0 -3.1 79.7 67.9 92.0
200 0.2 23.5 20.8 91.5 -0.3 16.5 15.7 93.5 -0.6 54.7 47.6 92.0
400 -1.8 14.5 14.7 95.5 0.7 11.8 11.1 92.5 -1.2 33.6 33.0 94.5
3 100 2.0 32.2 26.9 88.5 4.1 22.1 21.0 93.5 3.1 74.8 67.3 91.0
200 -3.3 19.6 18.9 94.5 0.6 15.3 14.6 92.0 5.8 50.5 45.6 91.5
400 1.0 15.9 13.4 89.5 0.7 10.6 10.2 93.0 -2.2 36.8 31.6 91.0
1 Note: These columns are in 10−3 scale
2 Note: SD refers to the standard deviation of the estimated parameters from 200 replicates, SE
refers to the mean of the estimated standard errors calculated by our covariance function, CP
refers to the coverage probability of the 95% confidence intervals calculated using the estimated
standard errors.
3 Note: The worst case Monte Carlo standard error for proportions is 2.3%.
Table 2: Estimated Parameters for Lag 3 Weighted Advantage from 200 Replicates
n α˜3 β˜3,0 β˜3,1 ¯˜τK(pˆi
opt
t , St)
(×10−2) (×10−2) (×10−2) (×10−3)
100 -40.6 (2.1) 2.8 (1.1) 63.0 (4.7) 64.7 (0.27)
200 -40.9 (1.4) 2.7 (0.8) 63.3 (3.2) 64.8 (0.13)
400 -40.7 (1.1) 2.7 (0.5) 62.9 (2.3) 64.9 (0.06)
1 Note: The numbers in the parenthesis are the standard
deviations.
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Table 3: Estimated Parameters for Lag 3 Weighted Advantage from 200 Replicates When
θ2 = −0.1
n α˜3 β˜3,0 β˜3,1 τ˜K(πˆ
opt
t , St)
100 -40.6 (2.1) 2.9 (1.1) 62.9(4.7) 63.9(0.46)
200 -40.9 (1.4) 2.7 (0.8) 63.3(3.2) 64.0(0.25)
400 -40.7 (1.0) 2.8 (0.5) 62.9(2.3) 64.1(0.17)
1 Note: Columns 2-4 are in 10−2 scale; column 5 is in 10−3
scale.
2 Note: The numbers in the parenthesis are the standard de-
viations.
3 Note: The last column τ˜K(pˆi
opt
t , St) =
∑T
t=1 τ˜t,K(a =
pˆioptt , St)/T .
each with observations from time t = 1, . . . , T + 3. Table 2 presents the average lag 3
weighted advantage across time ¯ˆτK =
∑T
t=1 τ˜t,K(a = πˆ
opt
t , St)/T . The average lag 3 weighted
advantage of the true optimal treatment regime is 65.0 × 10−3. As the result shows, the
treatment regimes estimated by the proposed method was close to optimal.
In order to see how the model performs when assumption (7) is not satisfied, we generate
the datasets with the same parameters except that θ2 = −0.1. Under this setting, assumption
(7) is not satisfied for k = 1 when St = Xt (see appendix for details). The result of the
simulation is presented in Table 3. The estimated parameters for β1,0 were biased, thus
leading to wrong statistical inference of the parameters. Since for k = 2, 3, assumption (7)
is still satisfied, the result remained unbiased (see appendix for the complete results). We
also calculate the average lag 3 weighted advantage of the treatment regime suggested by the
biased estimation equation with w = (1/3, 1/3, 1/3). The average lag 3 weighted advantage of
the true optimal treatment regime is 64.5×10−3, while the average lag 3 weighted advantages
of the estimated treatment regime are 63.9 × 10−3, 64.0 × 10−3 and 64.1 × 10−3 for sample
size 100, 200 and 400. In this particular setting, the recommended treatment regime was
still close to optimal. However, it cannot be guaranteed that the suggested treatment regime
would be close to optimal in a different setting. One solution to the bias is to include more
information in St. Under this specific setting, it is trivial to prove that Yt+k, At|Xt, At−1.
Therefore, by taking St = (Xt, At−1), we could obtain unbiased estimates of the parameters
using the same estimation equation. The estimated results with St = (Xt, At−1) are given in
the appendix.
5 Type 1 Diabetes Data Analysis
Rapid-reacting insulin therapies are frequently used for diabetes patients before meals to
prevent hyperglycemia events. However, the patients under the insulin therapies may be
constantly under the risk of hypoglycemia or hyperglycemia due to overdosing or underdosing.
Mobile technologies can provide real-time tracking on blood glucose, physical activity and
insulin injections of the patients and thus facilitate the dose adjustments to prevent adverse
events (Maahs et al., 2012). We apply our method to the Ohio type 1 diabetes dataset
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collected by Marling & Bunescu (2018) to estimate the lagged treatment effects of the doses
and then provide dose suggestions which maximize the weighted advantage2.
This dataset contains six patients, each with eight weeks of data, including: blood glucose;
insulin dosages, including rapid reacting insulin taken before meals (bolus insulin doses), and
long-term insulin infused continuously through out the day (basal insulin doses); sensor-
collected physiological measurements including heart rate, body temperature and steps; and
self-reported life-events including carbonhydrates intake and exercises. Through exploratory
analysis, we found that each patient has distinct patterns in insulin usage and blood glucose
levels. Therefore, we regard them as 6 separate datasets. We illustrate with the data of
one patient and assume that the data from each day of this patient are independent from
each other. Results of the other patients are presented in the appendix. There are 54 days
of data available. We further take the first 44 days as the training data and the last 10
days as the testing data. We summarize the measurements every 30 minutes, resulting in
T = 48 time intervals each day. For each 30-minute time interval, the covariates we consider
include total carbonhydrates intake, planned total carbonhydrates intake in the next time
interval, average glucose level, average heart rate and basal insulin level. We denote these
covariates as: Xt = (Carbt, Carb-Plannedt, Glucoset,Heartratet,Basalt)
T . Since education of
meal planning is typically incorporated as a part of the insulin therapy for diabetes patients
(Bantle et al., 2008), we assume that all the carbonhydrates intake within 30 minutes are
planned ahead of time and Carb-Plannedt = Carbt+1. At is the total bolus injection from
t− 1 to t. Let Amax be the maximum observed dose across all days and time. We estimate
A with the interval [0, Amax]. Yt is taken to be the average of the index of glycemic control
(IGC) between time t− 1 and t calculated by:
IGC = −I(G < 80)|80−G|
2
30
− I(G > 140)|G− 140|
1.35
30
where G is the measured blood glucose level (See Rodbard (2009) for various criterias for
glycemic control evaluation). Higher Yt indicates a better glycemic control within the time in-
terval. We take St = (X
T
t , Basal-4-8-hourt, At−1)
T , where Basal-4-8-hourt =
∑15
l=8 Basalt−l/8.
These covariates are chosen because they are significantly correlated with At from exploratory
analysis. To satisfy assumption (7), all covariates correlated with At need to be included in
St. We take f(St) = (Carbt, Carb-Plannedt,
∑15
k=8Basalt−k/8, At−1) and predict the treat-
ment effect of the dosage within two hours, k = 1, . . . , 4. Thus the model for the lag k causal
effect can be written as:
τk(a, St) = αka
2 + (βk,0 + βk,1Carbt + βk,2Carb-Plannedt + βk,3Basal-4-8-hourt + βk,4At−1)a
We still use Gaussian kernel and the bandwidth Λ is chosen to be a q × q diagonal matrix
with Λj,j = λ
2
j and λj = 0.305× n−1/8sd(St,j), where j = 1, ..., q and q = 7.
The estimated parameters are presented in Table 4. The optimal treatment would
be the one which maximizes the weighted advantage for two hours. Since the estimated
α˜K was negative, the optimal treatment regime at time t can be estimated by πˆ
opt
t =
−{ ˆ˜βTKSt}/(2 ˆ˜αK) when −{ ˆ˜βTKSt}/(2 ˆ˜αK) ∈ [0, Amax]; 0 when −{ ˆ˜βTKSt}/(2 ˆ˜αK) < 0; Amax when
2The R code for real data application can be found in https://github.com/lz2379/Mhealth.
12
Table 4: Estimated variables with the Ohio type 1 diabetes dataset
k 1 2 3 4 Weighted
αk (×10−2) -12.7(9.0) -20.6(14.8) -13.7(12.8) -5.2(12.1) -13.0(11.0)
βk,0 (×10−1) 15.8(8.2) 45.6(14.7) 50.0(11.1) 33.8(17.8) 36.9 (10.9)
βk,1 (×10−3) 21.8(10.8) 17.4(15.5) 15.3(18.7) 25.3(20.3) 15.2 (13.7)
βk,2 (×10−3) 25.1(10.1) 18.8(13.8) 8.8(14.5) 6.5(16.5) 13.8(11.9)
βk,3 (×10−1) -15.6(9.7) -40.5(14.8) -47.4(12.5) -35.2(18.7) 34.9(11.8)
βk,4 (×10−2) -6.1(11.6) -15.4(19.6) -8.2(24.9) -14.3(25.8) -9.1(18.3)
1 Note: The numbers in the parenthesis are the estimated standard errors calculated by the
covariance formula.
2 Note: The last column presents the estimated parameters for the lag 4 weighted advantage
with w1 = w2 = w3 = w4 = 1/4.
−{ ˆ˜βTKSt}/(2 ˆ˜αK) > Amax. Since ˆ˜αK < 0, the parameters ˆ˜βK,j can be interpreted as the units
of increase in optimal insulin with −2α˜K extra units in the St,j had the other covariates held
constant. The results implied that the optimal dose should be higher when the carbonhy-
drates intake was higher over the past half an hour or the planned carbonhydrates intake is
higher for the next half an hour ( ˆ˜βK,1,
ˆ˜βK,2 > 0); the optimal dose should be lower when the
average basal insulin rate 4 to 8 hours ago was higher or the dose in the last half an hour
was higher (
ˆ˜
βK,3,
ˆ˜
βK,4 < 0). These results are consistent with the fact that carbonhydrates
intake increases the blood glucose and past insulin injections lower the blood glucose. The
result also implies that the past basal insulin infusion rate is an important factor in deciding
the optimal insulin dosage for the current moment.
We then estimate the lag K weighted advantage on the test dataset using the estimated
parameters ˆ˜τt,K(a, St) = ˆ˜αKa
2+
ˆ˜
βKf(St). The mean of the estimated average lag 4 weighted
advantage
∑T
t=1 τ˜t,K(a, St)/T is 0.63 for the suggested treatment regime and 0.13 for the
original doses. If the model was correct, this method could be used to provide dose suggestions
which enhance the stability of the blood glucose for diabetes patients within two hours.
6 Discussion and Conclusion
In this article, we defined the lag k treatment effects for continuous treatments following
the framework by Boruvka et al. (2018). Nonparametric structural nested models with a
quadratic form were used for estimating the causal effects of continuous treatments based on
mobile health data. We also defined the weighted lag K advantage to measure the effect of
the treatments within a short time period in the future. The optimal treatment regime was
defined to be the one which maximizes this advantage. The R code for the simulations and
the real data application is provided in the supplementary material.
The proposed method fills the gap in the literature of sequential decision making where
the goal is to provide dose suggestions which maximize short-term outcomes. This semipara-
metric model provides more robustness against model misspecification. By conditioning on
partial information of the past history, the proposed method excludes irrelevant information
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for the estimation of the optimal treatment regime. Thus, the complexity of the suggested op-
timal dosage would not increase as T increases and is more practical when applied to infinite
horizon data. Compared to other infinite horizon methods where stationarity or Markovian
property is required, this method imposes minimal assumptions on the data generating pro-
cess. Statistical inference can also be provided for the estimated parameters. The simulation
studies showed that the method was capable of estimating the parameters accurately and
the variance could be approximated with our covariance function. The estimated treatment
regime was close to maximizing the weighted lag K advantage. Application to the Ohio type
1 diabetes dataset showed that this method could provide meaningful insights for dose sug-
gestions based on observed history of the patients. In practice, to ensure the unbiasedness of
proposed estimation equation, it is essential to include all confounders which influence both
At and Yt+k into St.
The proposed method is also subject to a few limitations. First, the proposed method is
limited to estimating the causal effect of a one-time change in the treatment history. Estimat-
ing the cumulative treatment effects if all future treatments follow the suggested treatment
regime would be of more interest in certain scenarios. However, the single-time change
measurement can still be of great use in practice. In real life, when patients are taking med-
ications, they are likely to take medications only a few times per day. It would be useful to
measure what would be the best dosage if the patient takes the medication at the moment
and conduct no further medical actions for the next few hours. Second, when the key assump-
tion (7) is not satisfied, the proposed method might lead to biased results. In Appendix C.2,
we showed that this bias can be avoided by including all variables that are influential to the
decision making process. In practice, for diseases like diabetes and hypertension (which are
the main applications we are interested in), patients typically receive education from clini-
cians on dosage calculation before starting the treatment. Take diabetes as an example. Key
decision-making factors, including meals, exercise levels, physical indicators, are collected
by most blood glucose monitoring applications. The proposed method can be applied to
enhance the performance of the dosages when the key factors for dosing are well established
for the patients and can be easily collected. However, the assumption (7) might be hard
to examine when the decision making process of the patient is unknown. Therefore, it is
definitely essential to let patients be aware of the possible fallacy of the method when an
outside factor is guiding his/her decision making process. Third, due to the quadratic form
of the model for the lagged treatment effects, a slight underestimate of the quadratic effects
of the doses may lead to a large overestimate of the optimal dose. Possible future work would
include improving the method to avoid overestimation in doses.
In the future, we are also interested in extending the method to incorporate both long-
term optimization and short-term monitoring. Applying this method to online streaming
data is also of great interest. For a fixed group of users, the proposed method can be
extended to allow streaming data without much additional computation. If the number of
users is large, kernel estimation would be computationally expensive. One potential solution
is to divide users into subgroups according to certain demographic or medical similarities and
then conduct kernel estimation within each subgroup.
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.1 Proof of Equation (2)
First, for the first term in equation (2), we can derive:
E
[
Yt+k(A¯t−1, a, A
at=a
t+1 , . . . , A
at=a
t+k−1)|Ht(A¯t−1)
]
= E
[
Yt+k(A¯t−1, a, A
at=a
t+1 , . . . , A
at=a
t+k−1)|Ht(A¯t−1), At = a
]
= E
[
Yt+k(A¯t−1, At, A
at=a
t+1 , . . . , A
at=a
t+k−1)|Ht(A¯t−1), At = a
]
= E
[
E
{
Yt+k(A¯t−1, At, A
at=a
t+1 , . . . , A
at=a
t+k−1)|Ht(A¯t−1), At = a, At+1 = Aat=at+1 , . . . ,
At+k−1 = A
at=a
t+k−1
}
|Ht(A¯t−1), At = a
]
= E
[
E
{
Yt+k|Ht(A¯t−1), At = a, At+1 = Aat=at+1 , . . . , At+k−1 = Aat=at+k−1
}
|Ht(A¯t−1), At = a
]
= E
[
Yt+k|Ht(A¯t−1), At = a
]
= E
[
Yt+k|Ht, At = a
]
,
where the first equation is based on the sequential ignorability assumption; The second,
the third and the fifth equations are based on the property of the conditional expectation;
The fourth and the last equations are based on the consistency assumption. Equation (2)
can thus be proved.
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.2 Proof of Equation (8)
We need to show that under assumptions (3) and (7) :
E
[{
d(At, St)− E(d(At, St)|St)
}
×
{
Ut+k −E(Ut+k|St)
}]
= 0.
By the property of conditional expectation, it is trivial to obtain that:
E
[{
d(At, St)−E(d(At, St)|St)
}
×E(Ut+k|St)
]
= E
(
E
[{
d(At, St)−E(d(At, St)|St)
}
×E(Ut+k|St)
∣∣∣∣∣St
])
= E
[
E
{
d(At, St)|St
}
−E
{
d(At, St)|St)
}
× E(Ut+k|St)
]
= 0.
Thus Equation (8) is equivalent to: E
[{
d(At, St) − E(d(At, St)|St)
}
× Ut+k
]
= 0. By the
property of conditional expectation, it is sufficient to show that:
E
[{
d(At, St)− E(d(At, St)|St)
}
× Ut+k
∣∣∣St] = 0,
which is equivalent to:
E
[
d(At, St)Ut+k|St
]
= E
[
d(At, St)|St
]
E
[
Ut+k|St
]
. (9)
From the definition of Ut+k, we can obtain that:
Ut+k = Yt+k − τk(At, a0, St).
With consistency assumption, Yt+k = Yt+k(A¯t−1, a = At, A
a=At
t+1 , . . . , A
a=At
t+k−1). Thus,
Ut+k = Yt+k(A¯t−1, at = At, Aat=Att+1 , . . . , A
at=At
t+k−1)− τk(At, a0, St).
By the consistency assumption , it is trivial to prove that St(A¯t−1) = St. Then,
E(Ut+k|St, At) = E
[
Yt+k(A¯t−1, at = At, Aat=Att+1 , . . . , A
at=At
t+k−1)− τk(At, a0, St)|St(A¯t−1), At
]
= E
[
Yt+k(A¯t−1, at = At, Aat=Att+1 , . . . , A
at=At
t+k−1)− E
{
Yt+k(A¯t−1, at = At, Aat=Att+1 , . . . , A
at=At
t+k−1)−
Yt+k(A¯t−1, at = a0, Aat=a0t+1 , . . . , A
at=a0
t+k−1)
∣∣∣Ht(A¯t−1), At}∣∣∣St(A¯t−1), At
]
.
We first take the conditional expectation with respect to Ht(A¯t−1), At. Then the first
term and the second term are both
E{Yt+k(A¯t−1, at = At, Aat=Att+1 , . . . , Aat=Att+k−1)|Ht(A¯t−1), At}
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and can be canceled. Thus the right side of the above equation is equal to:
E
[
E{Yt+k(A¯t−1, at = a0, Aat=a0t+1 , . . . , Aat=a0t+k−1)|Ht(A¯t−1), At}|St(A¯t−1), At
]
= E
[
Yt+k(A¯t−1, at = a0, A
at=a0
t+1 , . . . , A
at=a0
t+k−1)|St(A¯t−1), At
]
= E
[
Yt+k(A¯t−1, at = a0, A
at=a0
t+1 , . . . , A
at=a0
t+k−1)|St(A¯t−1)
]
,
where the last equation is based on assumption (7). Therefore,
E(Ut+k|St, At) = E
[
Yt+k(A¯t−1, at = a0, A
at=a0
t+1 , . . . , A
at=a0
t+k−1)|St(A¯t−1)
]
.
Take expectation with respect to St for both sides, we obtain that:
E(Ut+k|St) = E
[
Yt+k(A¯t−1, at = a0, A
at=a0
t+1 , . . . , A
at=a0
t+k−1)|St(A¯t−1)
]
= E(Ut+k|St, At).
Therefore,
E
[
d(At, St)Ut+k|St
]
= E
[
E{d(At, St)Ut+k|St, At}
∣∣∣St]
= E
[
d(At, St)E{Ut+k|St, At}
∣∣∣St]
= E
[
d(At, St)E{Ut+k|St}
∣∣∣St]
= E
{
d(At, St)|St
}
E
{
Ut+k|St
}
.
Thus Equation (9) can be proved. Therefore, Equation (8) is proved.
.3 Proof of Theorem 2
First of all,
√
n(φˆk − φ∗k)
=
[
PnL1(H ; Bˆ, Cˆ)
]−1[√
nPn
{
L2(H ; Bˆ, Cˆ, Dˆ)− L1(H ; Bˆ, Cˆ)φ∗k
}]
.
The second part on the right side can be written as:
√
nPn
{
L2(H ; Bˆ, Cˆ, Dˆ)− L1(H ; Bˆ, Cˆ)φ∗k
}
=
√
n
[
Pn{L2(H ; Bˆ, Cˆ, Dˆ)− L1(H ; Bˆ, Cˆ)φ∗k} − Pn{L2(H ;B,C,D)− L1(H ;B,C)φ∗k}
]
+
√
n
[
Pn{L2(H ;B,C,D)− L1(H ;B,C)φ∗k} − E{L2(H ;B,C,D)− L1(H ;B,C)φ∗k}
]
.
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Therefore, to prove Theorem 2, it is enough to show the following three equations:
PnL1(H ; Bˆ, Cˆ)
p−→ E[L1(H ;B,C)], (10)
√
n
[
Pn{L2(H ; Bˆ, Cˆ, Dˆ)− L1(H ; Bˆ, Cˆ)φ∗k} − Pn{L2(H ;B,C,D)− L1(H ;B,C)φ∗k}
]
= op(1), (11)
√
n
[
Pn{L1(H ;B,C)φ∗k − L2(H ;B,C,D)} − E{L1(H ;B,C)φ∗k − L2(H ;B,C,D)}
]
d−→ N
{
0,Σ(φ∗k;B,C,D)
}
. (12)
Then with Slutsky’s theorem, we can obtain that
√
n(φˆk − φ∗k) converges in distribution
to a mean zero normal random vector with variance-covariance matrix given by:
E−1
{
L1(H ;B,C)
}
Σ(H ;φ∗k, B, C,D)E
−1
{
L1(H ;B,C)
}
.
.3.1 Proof of Equation (10)
First, we can obtain:
PnL1(H ; Bˆ, Cˆ)−E[L1(H ;B,C)]
= {PnL1(H ; Bˆ, Cˆ)− PnL1(H ;B,C)}+ {PnL1(H ;B,C)− E[L1(H ;B,C)]}.
The second part on the right is op(1) by the law of large numbers. Therefore, we just need
to prove that the first part is op(1). With Taylor expansion and the mean value theorem, we
can obtain: ∣∣∣PnL1(H ; Bˆ, Cˆ)− PnL1(H ;B,C)∣∣∣
=
∣∣∣Pn{∂L1(H ;B,C)
∂B
∣∣∣
B′
(Bˆ −B) + ∂L1(H ;B,C)
∂C
∣∣∣
C′
(Cˆ − C)
}∣∣∣
≤
∣∣∣Pn{∂L1(H ;B,C)
∂B
∣∣∣
B′
(Bˆ −B)
}∣∣∣+ ∣∣∣Pn{∂L1(H ;B,C)
∂C
∣∣∣
C′
(Cˆ − C)
}∣∣∣,
for some B′ between Bˆ and B, and C ′ between Cˆ and C. Since,
∣∣∣Pn{∂L1(H ;B,C)
∂B
∣∣∣
B′
(Bˆ −B)
}∣∣∣ ≤ Pn
∣∣∣∣∣∂L1(H ;B,C)∂B
∣∣∣
B′
∣∣∣∣∣ sups∈S
∣∣∣Bˆ −B∣∣∣. (13)
Notice that:
E
∣∣∣∣∣∂L1(H ;B,C)∂Bt
∣∣∣
B′
∣∣∣∣∣
= E
(
2|B′t − A2t | |Ct −At|fk(St)
|Ct − At|fk(St) 0
)
.
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By assumption 3, we can obtain that E{|Ct − At|fk(St)} < ∞. Furthermore, E|B′t − A2t | ≤
E|B′t − Bt| + E|Bt − A2t | ≤ E|Bˆt − Bt| + E|Bt − A2t |. By assumption 3, we can obtain that
E{Bt − A2t} <∞. Thus, If we can prove that:
sup
s
|Bˆt(s)−Bt(s)| = op(1), (14)
then E
∣∣∣∂L1(H;B,C)∂B |B′∣∣∣ <∞. Since
Pn
∣∣∣∣∣∂L1(H ;B,C)∂B
∣∣∣
B′
∣∣∣∣∣ p−→ E
∣∣∣∣∣∂L1(H ;B,C)∂Bt
∣∣∣
B′
∣∣∣∣∣,
we obtain that:
Pn
∣∣∣∣∣∂L1(H ;B,C)∂B
∣∣∣
B′
∣∣∣∣∣ = Op(1).
Together with Equation (14), we obtain that the right side of Equation (13) is op(1). Similarly,
if we can prove that:
sup
s
|Cˆt(s)− Ct(s)| = op(1), (15)
then we can obtain:
Pn
∣∣∣∣∣∂L1(H ;B,C)∂C
∣∣∣
C′
(Cˆ − C)
∣∣∣∣∣ = op(1).
Thus we can obtain that:∣∣∣PnL1(H ; Bˆ, Cˆ)− PnL1(H ;B,C)∣∣∣ = op(1).
Together with PnL1(H ;B,C) − E[L1(H ;B,C)] p−→ 0 by the law of large numbers, we can
finish the proof for equation (10).
Below, we prove equation (15). Proof of equation (14) can be derived similarly. First,
let the density of St be fSt and fˆSt(s) = {
∑n
i=1Kλ(s − Sit)}/n. Write Cˆt(s) as: Cˆt(s) =
Cˆt,1(s)/fˆSt(s), where Cˆt,1(s) = {
∑n
i=1A
i
tKλ(s− Sit)}/n. Also let Ct,1(s) = Ct(s)fSt(s), then:
sup
s
|Cˆt(s)− C(s)| = sup
s
|Cˆt,1(s)
fˆSt(s)
− Ct,1(s)
fSt(s)
| =
sup
s
∣∣∣
{
Cˆt,1(s)− Ct,1(s)
}
fSt(s)− Ct,1(s)
{
fˆSt(s)− fSt(s)
}
fˆSt(s)fSt(s)
∣∣∣
≤ sup
s
∣∣∣ Cˆt,1(s)− Ct,1(s)
fˆSt(s)
∣∣∣+ sup
s
∣∣∣Ct,1(s)
{
fˆSt(s)− fSt(s)
}
fˆSt(s)fSt(s)
∣∣∣.
Under the boundedness of Ct,1(s) and the assumption that pSt(s) is uniformly bounded
away from 0, it suffices to show that:
sup
s
|Cˆt,1(s)− Ct,1(s)| → 0, (16)
sup
s
|fˆSt(s)− fSt(s)| → 0. (17)
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We demonstrate the proof for equation (16). Equation (17) can be proved similarly. First
notice:
sup
s
|Cˆt,1(s)− Ct,1(s)| ≤ sup
s
|Cˆt,1(s)− E{Cˆt,1(s)}|+ sup
s
|E{Ct,1(s)} − Ct,1(s)|. (18)
We prove the uniform convergence of the two parts on the right separately. First, we
obtain:
E{Cˆt,1(s)} = E{AtKΛ(s− St)}
=
∫
at
∫
st
atKΛ(s− st)fAt|St(at|st)fSt(st)dstdat
=
∫
st
Ct(s)|Λ−1/2|K
(
Λ−1/2(s− st)
)
fSt(st)dst.
Let v = Λ−1/2(s− st), then st = s−Λ1/2v. Let Vs = {v : s−Λ−1/2v ∈ S}, then the above
equation is equal to:∫
Vs
Ct(s− Λ1/2v)K(v)fSt(s− Λ1/2v)dv
=
∫
Vs
{
Ct(s)− vTΛ1/2C˙t(s′)
}
K(v)
{
fSt(s)− vTΛ1/2f˙St(s′′)
}
dv
= Ct(s)fSt(s)
{∫
Vs
K(v)dv
}
−
{
Ct(s)f˙St(s
′′)T + fStC˙t(s
′)T
}
Λ
1
2
{∫
Vs
vK(v)dv
}
,
where the first equation above is obtained by Taylor expansion; s′ and s′′ are vectors
on the segment connecting s and St; for any function g(s), g˙(s) = ∂g(s)/∂s. From the
assumptions, Λ → 0 as n → ∞, thus infs Vs → S. infs{
∫
Vs K(v)dv} = 1 − O(Λ1/2).∫
Vs vK(v)dv ≤
∫
S vK(v) = O(1). Thus E{Cˆt,1(s)} = Ct,1(s) + O(Λ1/2). Next, we prove
the uniform convergence of the first part of equation (18).
sup
s
|Cˆt,1(s)− E{Cˆt,1(s)}|
= sup
s
| 1
n
{
n∑
i=1
AitKΛ(s− Sit)} −E{AitKΛ(s− Sit)}|
= sup
s
∣∣∣ ∫
st
Ct(st)|Λ− 12 |K
(
Λ−
1
2 (s− st)
)
d
{
Fn(st)− F (st)
}∣∣∣,
where Fn(st) and F (st) denote the empirical cumulative distribution and the cumulative
distribution of St. Then with integration by part, the above equation is less or equal to:
|Λ− 12 | sup
s,st
∣∣∣Ct(st)K(Λ− 12 (s− st)){Fn(st)− F (st)}∣∣∣
+ sup
s
∣∣∣ ∫
S
[{
Fn(st)− F (st)
}
dCt(st)K
(
Λ−
1
2 (s− st)
)]∣∣∣
≤ ξ1|Λ− 12 | sup
st
|Fn(st)− F (st)|,
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where ξ is a constant and the last inequality can be derived by the assumption for the
boundedness of Ct(st) andK(·). By lemma 2.1 of Schuster (1969), we obtain that:PSt{supst |Fn(st)−
F (st)| > ǫ} ≤ ξ2 exp(−2nǫ2). Then:
P (sup
s
|Cˆt,1(s)− E{Cˆt,1(s)}| > ǫ)
≤ P (ξ1|Λ− 12 | sup
st
|Fn(st)− F (st)| > ǫ)
= P (sup
st
|Fn(st)− F (st)| > ǫ|Λ
1
2 |
ξ1
)
≤ ξ2 exp(−2nǫ
2|Λ|
ξ21
).
Thus, if 2n|Λ| → ∞ as n→∞, then the first part of equation (18) converges to 0. Equation
(16) is then proved. With similar proof for equation (17), we can obtain formula (15). This
ends the proof for formula (10).
.3.2 Proof of Equation (11)
First we write the left side of the equation as:
√
nPn
[{
L2(H ; Bˆ, Cˆ, Dˆ)− L1(H ; Bˆ, Cˆ, Dˆ)φ∗k
}
−
{
L2(H ;B,C,D)− L1(H ;B,C,D)φ∗k
}]
=
√
nPn
[ T−k+1∑
t=1
{Mˆt,1Mˆt,2 −Mt,1Mt,2}
]
=
T−k+1∑
t=1
√
nPn
[
{Mt,1(Mˆt,2 −Mt,2) +Mt,2(Mˆt,1 −Mt,1) + (Mˆt,1 −Mt,1)(Mˆt,2 −Mt,2)}
]
,
where,
Mˆt,1 =
(
A2t − Bˆt(St)
{At − Cˆt(St)}gk(St)
)
,
Mˆt,2 = Yt+k − Dˆt(St)−
(
A2t − Bˆt(St)
{At − Cˆt(St)}gk(St)
)T
φ∗k,
Mt,1 =
(
A2t − Bt(St)
{At − Ct(St)}gk(St)
)
,
Mt,2 = Yt+k −Dt(St)−
(
A2t − Bt(St)
{At − Ct(St)}gk(St)
)T
φ∗k.
Thus, it is sufficient to show that:
√
nPnMt,1(Mˆt,2 −Mt,2) = op(1), (19)√
nPnMt,2(Mˆt,1 −Mt,1) = op(1), (20)√
nPn(Mˆt,1 −Mt,1)(Mˆt,2 −Mt,2) = op(1). (21)
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We first prove equation (19). Let Gt,1 = A
2
t − Bt(St), Gt,2 = {At − Ct(St)}fk(St), Gt,3 =
Yt+k−Dt(St) and Gˆt,1 = A2t − Bˆt(St), Gˆt,2 = {At− Cˆt(St)}fk(St), Gˆt,3 = Yt+k−Dˆt(St). Then
equation (19) can be written as:
√
nPn
(
Gt,1
Gt,2
){
Gˆt,3 −Gt,3 +
(
Gˆt,1 −Gt,1
Gˆt,2 −Gt,2
)T
φ∗k
}
= op(1).
Therefore, it is equivalent to show all the following equations :
√
nPnGt,1{Gˆt,3 −Gt,3} = op(1);√
nPnGt,2{Gˆt,3 −Gt,3} = op(1);√
nPnGt,1{Gˆt,1 −Gt,1} = op(1);√
nPnGt,2{Gˆt,2 −Gt,2} = op(1);√
nPnGt,1{Gˆt,2 −Gt,2} = op(1);√
nPnGt,2{Gˆt,1 −Gt,1} = op(1). (22)
We show the proof of the last equation above. The rest of the equations can be proved
similarly. First write it as:
√
nPnGt,2{Gˆt,1 −Gt,1}
= −√nPn{At − Ct(St)}{Bˆt(St)− Bt(St)}.
Let Bˆt,1(s) =
∑n
j=1A
j
t
2
KΛ(S
j
t − s)/n, Bt,1(s) = Bt(s)fSt(s). Then Bˆt(s) = Bˆt,1(s)/fˆSt(s). If
we can obtain that
lim
n→∞
Var
{√
n|Λ1/2|
(
Bˆt,1(s)− Bt(s)fˆSt(s)
)}
<∞, (23)
then from appendix B.1 of Zhu et al. (2020), we obtain that: under the assumptions:
√
n|Λ1/2|
(
Bˆt,1(s)−
Bt(s)fˆSt(s)
)
converge in distribution to a mean 0 normal distribution. Together with equa-
tion 17 and the assumption that fSt(s) is bounded away from 0, we can obtain that,√
n|Λ| 12{Bˆt(St)−Bt(St)}
=
√
n|Λ| 12
{Bˆt,1(St)− Bt(St)fˆSt(St)
fSt(St)
}
+ op(1)
=
√
n|Λ| 12
{ 1
n
n∑
j=1
B˜jt (St)KΛ(S
j
t − St)
}
+ op(1),
where B˜jt (s) = {A2t − E(A2t |St = s)}/fSt(s).
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Then:
√
nPnGt,2{Gˆt,1 −Gt,1}
= −√nPn{At − Ct(St)}{Bˆt(St)− Bt(St)}
= − 1
n
√
|Λ 12 |
n∑
i=1
{
Ait − Ct(Sit)
}[√
n|Λ 12 |
{
Bˆt(S
i
t)− Bt(Sit)}
]
= − 1
n
√
|Λ 12 |
n∑
i=1
{
Ait − Ct(Sit)
}[√
n|Λ 12 |
{ 1
n
n∑
j=1
B˜jt (S
i
t)KΛ(S
j
t − Sit)
}
+ op(1)
]
= −
√
n
n2
n∑
i=1
{
Ait − Ct(Sit)
}{ n∑
j=1
B˜jt (S
i
t)KΛ(S
j
t − Sit)
}
+ op(1)
= −
√
n
n2
n∑
i=1
n∑
j=1
{
Ait − Ct(Sit)
}
B˜jt (S
i
t)KΛ(S
j
t − Sit) + op(1).
The third equation above is based on
√
n|Λ 12 | → ∞ and
√
n
n
∑n
i=1(A
i
t − Ct(Sit)) d−→
N(0, E{Var(At|St}). Thus we just need to prove that the first term is op(1). The first term
above is a
√
n times a U-statistic plus an op(1) term when written as:
√
n
n2
n∑
j=1
∑
i<j
[
B˜jt (S
i
t)KΛ(S
j
t − Sit){Ait − Ct(Sit)}+ B˜it(Sjt )Kλ(Sjt − Sit)
{
Ajt − Ct(Sjt )
}]
+
1
n
[√
n
n
n∑
i=1
B˜it(S
i
t)
{
Ait − Ct(Sit)
}]
.
The second term above is op(1) because of the law of large numbers. The expectation of
the U-statistics is equal to :
n− 1
n
E
[
B˜jt (S
i
t)KΛ(S
j
t − Sit)
{
Ait − Ct(Sit)
}]
=
n− 1
n
E
[Ajt2 −E(A2t |St = Sit)
fSt(S
i
t)
KΛ(S
j
t − Sit)
{
Ait −E(At|St = Sit)
}]
=
n− 1
n
E
(
E
[{
Ait −E(At|St = Sit)
}∣∣∣Sit , Ajt , Sjt ]Ajt
2 −E(A2t |St = Sit)
fSt(S
i
t)
Kλ(S
j
t − Sit)
)
= 0.
By the properties of U-statistics, the variance of
√
n times the U-statistics converge to:
Var
{
E
[
B˜jt (S
i
t)KΛ(S
i
t − Sjt ){Ait − Ct(Sit)}+ B˜it(Sjt )KΛ(Sjt − Sit){Ajt − Ct(Sit)}
∣∣∣Sit , Ait]}.
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We can obtain:
E
[
B˜jt (S
i
t)KΛ(S
j
t − Sit){Ait − Ct(Sit)}+ B˜it(Sjt )Kλ(Sit − Sjt ){Ajt − Ct(Sjt )}
∣∣∣Sit , Ait]
= E
[
B˜jt (S
i
t)KΛ(S
j
t − Sit){Ait − Ct(Sit)}|Sit, Ait
]
= E
[
{Ajt
2 −Bt(Sit)}KΛ(Sjt − Sit)|Sit, Ait
]Ait − Ct(Sit)
fSt(S
i
t)
.
From calculation in section .3.1, we can obtain that:
sup
s
|E{Ajt
2
KΛ(S
j
t − s)} − Bt(s)fSt(s)| = O(|Λ
1
2 |)
sup
s
|E{KΛ(Sjt − s)} − fSt(s)| = O(|Λ
1
2 |).
Thus,
E
[
{Ajt
2 − Bt(Sit)}KΛ(Sjt − Sit)|Sit , Ait
]
≤ ξ3|Λ| 12 .
for some constant ξ3. Thus,
Var
{
E
[
B˜jt (S
i
t)KΛ(S
i
t − Sjt ){Ait − Ct(Sit)}+ B˜it(Sjt )KΛ(Sjt − Sit){Ajt − Ct(Sit)}
∣∣∣Sit , Ait]}
≤ ξ2|Λ|Var{A
i
t − Ct(Sit)
fSt(S
i
t)
}.
Then as long as Var{(Ait − Ct(Sit))/fSt(Sit)} <∞, the variance of the U-statistics converges
to 0. Since we assumed that fSt(s) is bounded away from 0 and E(A
2
t |St = Sit) < ∞, this
conditional can be satisfied. Thus, both the expectation and the variance of the
√
n times
the U-statistics converge to 0, so
√
n times the U-statistic converges in probability to 0. Thus
equation (22) can be proved. With similar proof for the other equations above equation (22),
we can obtain equation (19). Equation (20) can be proved similarly. Equation (21) can be
proved with similar calculation. We omit the details here due to the length of the proof. This
completes the proof for equation (11).
.4 Proof for Equation (12)
Equation 12 can be simply obtained with the central limit theorem. Thus the proof for
theorem is completed.
.5 Form for lag k effect under the simulation setting
The true value for the lag 2 effect is:
E(Yt+2|At = a, St)−E(Yt+2|At = 0, St) =
− (τ1η2 + τ2 − β1η2)(τ2 + τ1η2)a2 +
{
θ1η2 + θ2 + β0(τ1η2 + τ2)
}
a
+
{
(τ1η2 + τ2)(−2τ1η1 + β1η1) + β1τ1η1η2
}
aXt.
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For k ≥ 3: If we have:
E(Yt+k−1|At = a, St) = αk−1,1Xt + αk−1,2X2t + αk−1,3A2t + αk−1,4At + αk−1,5AtXt.
Then
E(Yt+k|At = a, St)
= αk−1,1Xt+1 + αk−1,2X2t+1 + αk−1,3A
2
t+1 + αk−1,4At+1 + αk−1,5At+1Xt+1
= αk−1,1(η1Xt + η2At) + αk−1,2(η1Xt + η2At)2 + αk−1,3
{
τ1η1Xt + (τ1η2 + τ2)At
}2
+ αk−1,4
{
τ1η1Xt + (τ1η2 + τ2)At
}
+ αk−1,5
{
τ1η1Xt + (τ1η2 + τ2)At
}
(η1Xt + η2At)
= αk,1Xt + αk,2X
2
t + αk,3A
2
t + αk,4At + αk,5AtXt,
where
αk,1 =
{
αk−1,1 + αk−1,4τ1
}
η1,
αk,2 =
{
αk−1,2 + αk−1,3τ 21 + αk−1,5τ1
}
η21,
αk,3 =
{
αk−1,2η22 + αk−1,3(τ1η2 + τ2)
2 + αk−1,5(τ1η2 + τ2)η2
}
,
αk,4 =
{
αk−1,1η2 + αk−1,4(τ1η2 + τ2)
}
,
αk,5 =
{
2η1η2αk−1,2 + αk−1,32τ1η1(τ1η2 + τ2)+
αk−1,5
[
τ1η1η2 + η1(τ1η2 + τ2)
]}
.
Then lag k effect is:
αk,3A
2
t + αk,4At + αk,5AtXt.
.6 Proof of Assumption (7) under the Simulation Setting
According to the data generation model for our simulation setting,
Yt+1(A¯t−1, at = a) = θ1Xt + θ2At−1 − a(a− β0 − β1Xt) + ǫt+1.
At ∼ Normal(τ1Xt + τ2At−1).
When θ2 = 0,
Yt+1(A¯t−1, at = a) = θ1Xt − a(a− β0 − β1Xt) + ǫt+1.
is independent of At given St = Xt. Thus assumption (7) is satisfied for k = 1. However,
when θ2 6= 0, this assumption is not satisfied for k = 1.
For k = 2, first since Xt+1(A¯t−1, at = 2) ∼ Normal(η1Xt + η2At, σ2), it is trivial to see
that:
Xt+1(A¯t−1, at = a) ⊥ At|Xt. (24)
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Table 5: Simulation results from 200 replicates when θ2 = −0.1.
αk βk,0 βk,1
k n Bias1 SD1 SE1 CP Bias1 SD1 SE1 CP Bias1 SD1 SE1 CP
2 100 1.9 31.4 29.2 91.5 -1.2 23.4 22.4 93.5 -4.7 79.1 68.3 93.0
200 -1.0 23.8 20.9 91.5 -0.1 16.6 15.8 93.0 3.6 56.3 47.9 90.5
400 -1.1 14.8 14.8 95.5 1.0 11.9 11.1 93.5 1.0 33.6 33.2 95.0
3 100 2.0 32.2 26.8 88.5 4.2 22.2 21.1 94.0 2.9 75.1 67.1 90.5
200 -3.1 19.5 18.8 93.0 0.6 15.6 14.7 91.5 5.3 50.8 45.7 92.0
400 1.1 15.7 13.3 89.5 0.7 10.8 10.3 94.0 -2.5 36.7 31.5 92.0
1 Note: These columns are in 10−3 scale
2 Note: SD refers to the standard deviation of the estimated parameters from 200 replicates, SE
refers to the mean of the estimated standard errors calculated by our covariance function, CP
refers to the coverage probability of the 95% confidence intervals calculated using the estimated
standard errors.
3 Note: The worst case Monte Carlo standard error for proportions is 2.3%.
Since
At+1(A¯t−1, at = a) ∼ Normal
(
τ1Xt+1(A¯t−1, at = a) + τ2at, σ2
)
,
we can obtain that
At+1(A¯t−1, at = a) ⊥ At|Xt. (25)
Therefore,
Yt+2(A¯t−1, at = a, A
at=a
t+1 ) =
θ1Xt+1(A¯t−1, at = a) + θa− At+1(A¯t−1, at = a)
{
At+1(A¯t−1, at = a)− β0−
β1Xt+1(A¯t−1, at = a)
}
+ ǫt+2
is independent of At given Xt based on Equation (24) and (25). This is true even when
θ2 6= 0.
Using induction, we can also prove that for any k ≥ 3,
Yt+k(A¯t−1, at = a, At+1, . . . , At+k−1) ⊥ At|Xt.
.7 Additional Simulation Results
The true parameters for k = 2, 3 when θ2 = −0.1 are : (α2, β2,0, β2,1) = (−0.21, 0.06,−0.08);
(α3, β3,0, β3,1) = (−0.0125,−0.05,−0.03). Table 5 presents the result for the estimated pa-
rameters when St = Xt. As shown in the table, the estimated parameters appeared to be
unbiased.
For k = 1, we can correct the bias by estimating the parameters with St = (Xt, At−1).
The model for the lag 1 treatment effect is thus: τt,1 = α1a
2 + (β1,0a + β1,1Xt + β1,2At−1)a.
The true parameters are: (α1, β1,0, β1,1, β1,2) = (−1, 0, 2, 0). Since the dimension of St has
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Table 6: Simulation results from 200 replicates when θ2 = −0.1.
k n Parameter Bias1 SD1 SE1 CP
1 100 αk 18.3 23.4 21.8 83.5
βk,0 11.7 15.9 14.8 82.0
βk,1 -20.5 59.3 54.5 91.5
βk,2 12.8 32.9 31.2 90.5
200 αk 9.2 13.8 15.0 92.5
βk,0 6.6 12.2 10.3 85.5
βk,1 -5.2 35.5 37.5 97.0
βk,2 4.6 21.1 21.3 95.5
400 αk 5.3 11.0 10.5 92.0
βk,0 3.4 8.1 7.3 88.0
βk,1 -2.6 28.4 26.1 93.0
βk,2 1.7 14.5 14.9 96.0
1 Note: These columns are in 10−3 scale
2 Note: SD refers to the standard deviation of the es-
timated parameters from 200 replicates, SE refers
to the mean of the estimated standard errors calcu-
lated by our covariance function, CP refers to the
coverage probability of the 95% confidence intervals
calculated using the estimated standard errors.
3 Note: The worst case Monte Carlo standard error
for proportions is 2.3%.
increased, we use the bandwidth λj = n
−1/4sd(St,j). The estimated parameters are presented
in Table 6. From the results we see that the estimated parameters appeared to be unbiased.
However, the estimated standard deviation was smaller than the actual standard deviation,
leading to lower coverage probability when sample size was small. This implies that when
the dimension of covariates increases, the estimated standard error converges slower to the
actual standard deviation.
.8 Additional Results for Ohio Type 1 Diabetes Dataset
We applied the proposed method for the Ohio Type 1 Diabetes Dataset. The dataset consists
of data from 6 patients. The result for patient 6 has been presented in the article. In Table
7, we present the additional results from the other patients. It is likely that the decision
process for insulin dosage is different for each patient. Thus using the same set of St for all
patients might not be the optimal choice.
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Table 7: Estimated variables with the Ohio type 1 diabetes dataset
Patient 1
k 1 2 3 4 Weighted
αk 17(7.6) 21.8(10.6) 16.6(10.6) 10.9(12.7) 16(9.1)
βk,0 -172.3(73.1) -92.3(103.9) -11(112.4) -50(116.4) -63.2(86.3)
βk,1 1.4(0.7) 3.1(1.4) 3.6(1.6) 3.3(1.7) 3.1(1.3)
βk,2 -0.8(3.1) 2.1(4.7) 5.9(4.8) 3.9(5.9) 2.9(3.6)
βk,3 -9.1(51.5) -104.4(80.4) -93.7(88.3) 34.9(66.7) -59.6(56.9)
βk,4 12.9(8.9) 2.6(19.2) -11.6(23) -170(35.2) -110.4(33.6)
Patient 2
k 1 2 3 4 Weighted
αk 0.2(0.7) 0.5(0.8) 0.6(1) -0.8(1.1) 0.1(0.8)
βk,0 -8.8(11.1) 14.1(18) 18(22.6) 14.7(24.2) 10.7(17.8)
βk,1 0.6(0.3) -0.2(0.2) 0(0.2) -0.1(0.5) 0.1(0.2)
βk,2 0.4(0.1) 0.2(0.3) 0.1(0.3) 0.3(0.3) 0.3(0.2)
βk,3 -2.6(6.8) -19.1(16.1) -22.2(22.5) -5.3(23.8) -13.1(16.9)
βk,4 -2.1(2.2) -3(4) -4.6(4.5) -6.3(5.2) -4.2(4)
Patient 3
k 1 2 3 4 Weighted
αk 0.6(1) -2.2(1.8) -5(2.6) -4.6(2.9) -2.9(1.9)
βk,0 -14(39.7) 69.2(57.3) 159.8(81.9) 173.5(88.3) 98.8(63.9)
βk,1 0.1(0.1) 0.4(0.3) 0.6(0.4) 0.7(0.4) 0.4(0.3)
βk,2 0.1(0.1) 0.2(0.2) 0.4(0.3) 0.3(0.3) 0.3(0.2)
βk,3 -11.2(46.6) -78.1(67.3) -148.4(93.1) -166(98.1) -103.3(74.8)
βk,4 2.3(2.5) 3.4(2.9) 5.9(3.3) 7.5(3.2) 4.8(2.7)
Patient 4
k 1 2 3 4 Weighted
αk -1.2(5.1) -7.4(5.9) -6.5(4.8) -5.8(4.6) -6.2(4.4)
βk,0 -129(138.1) 162.5(95.5) 154.2(124.4) 167.4(104.2) 97.8(72.4)
βk,1 0.2(0.4) 0.1(0.5) -0.8(0.7) -0.4(1) -0.1(0.5)
βk,2 0.4(0.5) 1.3(0.9) 1.2(0.8) 1.2(0.8) 0.7(0.6)
βk,3 130.6(169.5) -173.4(130.2) -146.4(162.6) -182.3(143.9) -96(97)
βk,4 1.2(3.5) -8.2(10.1) -13.9(12.3) -21.2(9.7) -10.3(7.7)
Patient 5
k 1 2 3 4 Weighted
αk 2.7(2.9) 6.7(4.4) 6.6(4.9) 2.7(5.2) 3.9(3.7)
βk,0 -271(110.8) -514.8(139.1) -321(160.8) -110.6(151.9) -303.4(127.8)
βk,1 0.4(0.3) 1.2(0.7) 0.1(0.7) -0.6(0.8) 0.3(0.6)
βk,2 0.6(0.3) 0.5(0.6) 0.5(0.7) 0.8(0.7) 0.6(0.5)
βk,3 173.1(87.1) 324.2(119.8) 201.9(134.1) 78.7(125.6) 198.1(103.7)
βk,4 28.8(13) 12.4(10.8) -5.1(6) -1.6(13.2) 8.4(7.8)
1 Note: These columns are in 10−2 scale .
2 Note: The numbers in the parenthesis are the estimated standard errors calculated
by the covariance formula.
3 Note: The last column presents the estimated parameters for the lag 4 weighted
advantage with w1 = w2 = w3 = w4 = 1/4.
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